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Artemisinin-based combination therapies (ACTs) are recommended for the treatment of uncomplicated 
falciparum malaria. Artemisinin derivatives are potent, rapidly acting antimalarias that reduce 
gametocyte carriage and patient infectivity; the sustained use of artesunate – amodiaquine reduced 
falciparum malaria transmission and progression of drug resistance. High efficacy of artemisinin-based 
combinations (artesunate
 
plus amodiaquine) was observed in areas where malaria is endemic. This 
paper describes a routine, simple, precise, economical and reproducible thin layer chromatographic 
technique for the detection of artesunate and amodiaquine in tablet dosage form. Chromatographic 
separation was performed on glass silica gel plates (20 × 20 cm), paraffin – n-hexane (2:3 v/v) and 
ethylacetate – toluene (2.5:47.5 V/V) as mobile phases. Artesunate exhibited a detection limit of 0.001 
mg/ml, while that of amodiaquine was 0.05 mg/ml. The two drugs were satisfactorily resolved with mean 
Rf values of 0.04 ± 0.03 and 0.06 ± 0.07 for artesunate and amodiaquine, respectively. The accuracy and 
reliability of the method was assessed by evaluation of linearity (0.001 – 6.0 and 0.05 – 6.0 mg/ml for 
artesunate and amodiaquine), precision (intraday RSD 10.68 – 25.78% and interday RSD 10.68 – 20.17 
for artesunate, and intraday RSD 8.25 – 37.26% and inter day RSD 8.25 – 19.74% for amodiaquine) and 
specificity, in accordance with International Conference for Harmonization (ICH) guidelines. The method 
developed can be used for the analysis of ten or more formulation on a single plate and is a rapid and 
cost-effective quality-control tool for routine analysis of artesunate and amodiaquine as the parent drug 
and in tablet formulations. 
 





More than 600 million people worldwide are infected with 
malaria (WHO, 2003) and an average of 1 to 2 million die 
every year, most of them are below the age of five. 
Several non-ACTs (artemisinin-based combination 
therapies) have been used to fight this infectious disease, 
but only ACTs have continued to show efficacy with no or 
minimal reported cases of resistance (Bonifacio, 2004.). 
Malaria is one of the leading causes of morbidity and 
mortality
 
worldwide (Snow et al., 2005). The spread of 
parasite resistance to first-line
 
drugs adds to the burden 
of the disease (Greenwood et  al.,  2005). A contributing 
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because
 
of the difficulty to assess their efficacy in vivo. 
Methodological
 
issues still being debated include how 
long patients should
 
be monitored after treatment and 
whether clinical or parasitological
 
outcomes should be 
given greater weight. Methods used so far
 
differ greatly, 
making comparison and synthesis of data very
 
difficult 
(Talisuma et al., 2004). The WHO has issued different 
sets of guidelines,
 
shifting emphasis with time from 
parasitological to clinical
 
assessment and more recently 
recommending that patients
 
be assessed both 





for 28 days if true failures are to be 
distinguished from new
 
infections; it also makes provision 
for the use of life table
 
analysis of results (WHO, 2003). 
Malaria is one of the three major infectious diseases 





2005). After World War II, the successful use of 
chloroquine as an efficient antimalaria drug against the 4 
strains of human Plasmodia (vivax, malariae, ovale and 
falciparum) and the cheap DDT insecticide significantly 
reduced the importance of this tropical disease up to 
1960. Unfortunately, the emergence of parasite strains 
resistant to chloroquine and other classical drugs was at 
the origin of the comeback of malaria (>200 million 
people are infected each year and there are >1 million 
deaths) (White et al., 1999). Resistance of mosquitoes to 
some insecticides has been documented just within a few 
years after the insecticides were introduced. There are 
over 125 mosquito species with documented resistance 
to one or more insecticides. The development of resis-
tance to insecticides used for indoor residual spraying 
was a major impediment during the Global Malaria 
Eradication Campaign. Judicious use of insecticides for 
mosquito control can limit the development and spread of 
resistance. However, use of insecticides in agriculture 
has often been implicated as contributing to resistance in 
mosquito populations (CDC, 2004). 
Fortunately, antimalarial drug research is active again 
after a decline period of several decades (Nwaka and 
Ridley, 2003). The renewal of activity in this field is 
caused mainly by the design of new small molecules 
active against chloroquine-resistant (CQR) strains of 
Plasmodium falciparum. With a chemical structure 
significantly different from that of quinoline-based drugs, 
the natural product artemisinin and its derivatives have 
attracted the attention of many different groups regarding 
the mechanism of action of these potent antimalarias 
devoid of significant clinical resistance up to now in Africa 
(Meshnick et al., 1996; Robert et al., 2005; Olliaro et al., 
2001; Wu, 2002; Eckstein-Ludwig et al., 2003). 
Artemisinin, with its 1,2,4-trioxane as active motif, has 
served as a source of motivation for the design of 
synthetic peroxide-containing drugs (Jefford, 2007; 
Posner et al., 2008; O’Neill and Posner, 2004; 
Vennerstrom et al., 2004; Singh et al., 2006). Artemisinin 
(qinghaosu) has been used for centuries in traditional 
Chinese medicine for the treatment of fever. In 1972, 
Chinese scientists isolated the active principle from the 
plant Artemisia annua. Artemisinin is a sesquiterpene 
lactone charac-terized by the presence of an endo-
peroxide that is associated with its potent antimalarial 
activity. Because artemisinin is chemically unstable and 
poorly soluble in water or oil, the carbonyl group at C-10 
of the parent compound is often reduced to obtain 
dihydroartemisinin. Several derivatives have been 
developed by adding ether, ester or other substituents to 
the hydroxyl group of dihydroartemisinin. These semi-
synthetic derivatives include water soluble derivatives, 
sodium artesunate and artelinic acid and the oil-soluble 
derivatives, artemether and arteether. With the exception 
of arteether and artelinic acid, these compounds are used 
to treat malarial infections in endemic countries (Ringwald 
et al., 1999).  Artemisinin     derivatives     are     available     




in different formulations for oral, parenteral and rectal 
administration. Clinical studies have shown that 
artemisinin derivatives are highly potent, rapidly acting 
and well-tolerated blood schizontocides, resulting in short 
parasite clearance times as compared to other 
antimalarial drugs. Artemisinin derivatives are highly 
effective against P. falciparum isolates that are resistant 
to other drugs. These derivatives are indicated for the 
emergency treatment of severe and complicated 
falciparum malarial by parenteral administration and for 
the oral treatment of uncomplicated multidrug-resistant 
malaria. All the artemisinin derivatives are metabolized 
rapidly to the active metabolite dihydroartemisinin, which 
is more active than the other artemisinin derivatives. The 
use of dihydroartemisinin instead of the substitute 
compounds (example, artesunate or artemether) has 
advantages. The drug is easy to produce with less 
synthetic steps, and thus a lower cost (http:/www.Rdi. 
gpo.or.th/htmls/dihyro.html). Dihydroartemisinin is 
thermally labile, lacks ultraviolet absorbence or 
fluorescent chromophore and does not possess 
functional groups for derivatization. Therefore, the 
development of sensitive and specific analytical methods 
for determination of dihydroar-temisinin is a challenging 
problem. Several techniques have been used to address 
this problem, such as gas chromatography (GC), and gas 
chromatography combined with mass spectrophotometry, 
e.t.c. However, presently, there is no cheap, simple and 
reliable analytical method available, which can be used to 
follow up the history of people undergoing a treatment as 
well as to identify counterfeit and substandard anti-
malarial drugs in circulation. Furthermore, there is no 
single simple semi-quantitative method, which can be 
used to detect more than one anti-malarial drug using the 
same test system and conditions. This means that there 
is a shortage of simple and convenient analytical 
methods for monitoring antimalarial drug quality, usage, 
adequate absorption and excretion (Bojang et al., 2005). 
The purpose of this research was to establish and 
validate, in accordance with International Conference on 
Harmoni-zation (ICH) guidelines, a routine, simple, 
precise, economical and reproducible thin layer chroma-
tographic technique for the detection of artesunate and 
amodiaquine in commercial antimalarial drugs. 
 
 




The antimalarial drugs- artesunate and amodiaquine, were 
generous gift from the Department of Paediatrics, University 
College Hospital, Ibadan. 
 
 
Preparation of stock solution of artesunate and amodiaquine 
 
One tablet of commercial artesunate tablet containing 5 mg of 
artesunate was dissolved in 50 ml of dimethyl sulfoxide  (DMSO), to 








Distance moved by mobile 
phase solvent front 




0.001 10.4 0.1 0.009 
0.00125  0.1 0.009 
0.0025  0.1 0.009 
0.005  0.1 0.009 
0.01  0.1 0.009 
0.0125  0.1 0.009 
0.025  0.2 0.019 
0.05  0.2 0.019 
0.1  0.3 0.029 
0.125  0.4 0.038 
0.25  0.5 0.048 
0.5  0.7 0.067 
1.0  0.5 0.048 
2.0  0.6 0.058 
3.0  0.6 0.058 
4.0  0.7 0.067 
5.0  0.4 0.038 




obtain a stock containing 50 mg/50 ml of artesunate in DMSO. One 
tablet of commercial base amodiaquine tablet containing 200 mg of 
amodiaquine in the form of a base was dissolved in 50 ml of 
dimethylsulfoxide (DMSO), to give a stock containing 200 mg/50 ml 
of amodiaquine in DMSO. 
 
 
Preparation of calibration curves 
 
To prepare the calibration curve for the artesunate, accurately 
measured aliquots were taken from the stock solution, each aliquot 
corresponding to 0.001, 0.00125, 0.0025, 0.005, 0.01, 0.0125, 
0.025, 0.05, 0.1, 0.125, 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/ml, 
respectively. Different solvents and solvent combinations were 
tested for their abilities to separate the drugs from excipients in their 
formulations. Some of the tested solvent combinations include, 
ethyl acetate: toluene, ethyl acetate: toluene: isopropanol, hexane: 
toluene: paraffin mixtures. However, the plates were developed with 
50 ml of paraffin- n hexane mixture 2:3 (v/v). 
To prepare the calibration curve for amodiaquine, accurately 
measured aliquots was taken from the stock solution, each aliquot 
corresponding to 0.05, 0.1, 0.125, 0.25, 0.5, 1.0, 2.0, 3.0, 4.0 and 
5.0 mg/ml, respectively. Different solvents and solvent combinations 
were tested. Some of the tested solvent combinations include: 
isopropanol-n hexane, cyclohexanol-toluene, methylamine- n 
hexane, ethyacetate-toluene-isopropanol, hexane-toluene-paraffin 
mixtures, tetrahydrofuran-paraffin-cyclohexanol-water and 
tetrahydrofuran-paraffin-isopropanol-cyclohexanol. However, the 
plates were developed with 50 ml of ethyacetate-toluene mixture 
(2.5: 47.5) (v/v). 
 
 
Spotting of the TLC plates 
 
A 20 × 20 cm prepared glass TLC plates were used for the 
separations. Samples were spotted on the TLC plates at a distance 




Development of the spotted TLC plates 
 
The spotted plate was developed in a chromatographic tank with 
paraffin- n hexane mixture, 2:3 (v/v) as mobile phase for artesunate 
and ethyacetate-toluene mixture, 2.5: 47.5 (v/v) as mobile phase for 
amodiaquine. The plate was allowed to develop for 20, 22 and 25 
min at a development distance of 10.0, 10.4 and 10.8 cm, 
respectively, for artesunate and 9.4, 12.5 and 12.8 cm, respectively, 
for amodiaquine, for both intraday and interday determinations. 
After separations, the plates were allowed to dry at ambient 
temperature for 5 min and then transferred to the iodine tank for 
colour development. The development time was 25 min. The 
retention factor (Rf) values were determined for each concentration 
of the sample solution as presented in Table 1. 
The procedure was repeated twice on the same day and 





The method was validated for linearity, specificity, intra-day and 
inter-day precision, repeatability of measurement of peak area, and 
repeatability of sample application, in accordance with International 
Conference on Harmonisation (ICH) guidelines (ICH, 1994). The 
robustness of the method was studied, during method 
development, by determining the effects of small variations of 
mobile phase composition (+2%), development chamber saturation 
period and development distance as shown in Table 3. Intra-day 
precision was determined by analysis of solutions of artesunate and 
amodiaquine in the range of 0.1 to 6.0 mg/ml, three times on the 
same day (Tables 2a and 4a and b). Inter-day precision was 
determined by analysis of similar standards on three different days 
over a period of two weeks. Relative standard deviation (RSD) was 
calculated for both series of analyses. 








Distance moved by mobile phase 
solvent front 




0.001 10.8 0.3 0.03 
0.00125 10.8 0.4 0.04 
0.0025 10.8 0.4 0.04 
0.005 10.8 0.4 0.04 
0.01 10.8 0.4 0.04 
0.0125 10.8 0.4 0.04 
0.025 10.8 0.4 0.04 
0.05 10.8 0.4 0.04 
0.1 10.8 0.5 0.05 
0.125 10.8 0.5 0.05 
0.25 10.8 0.7 0.06 
0.5 10.8 0.9 0.08 
1.0 10.8 1.0 0.09 
2.0 10.8 1.1 0.10 
3.0 10.8 1.0 0.09 
4.0 10.8 1.0 0.09 
5.0 10.8 1.2 0.11 




Table 1c. Data for artesunate retention factor (Rf) values (within Day 2). 
 
Concentration (µg/ml) Distance moved by mobile phase(solvent front Distance moved by sample Retention factor (Rf) 
0.001 10.0 0.0 0.00 
0.00125 10.0 0.0 0.00 
0.0025 10.0 0.0 0.00 
0.005 10.0 0.0 0.00 
0.01 10.0 0.0 0.00 
0.0125 10.0 0.0 0.00 
0.025 10.0 0.0 0.00 
0.05 10.0 0.0 0.00 
0.1 10.0 0.2 0.02 
0.125 10.0 0.3 0.03 
0.25 10.0 0.2 0.03 
0.5 10.0 0.3 0.04 
1.0 10.0 0.4 0.05 
2.0 10.0 0.5 0.06 
3.0 10.0 0.6 0.07 
4.0 10.0 0.8 0.08 
5.0 10.0 0.8 0.08 




RESULTS AND DISCUSSION 
 
Tablet powder of artesunate and amodiaquine were 
pulverized and dissolved in dimethylsulfoxide. Several 
solvents for example, ethyl acetate-toluene, ethyl 
acetate-toluene-isopropanol, hexane-toluene-paraffin 
mixtures and Isopropanol-n hexane, cyclohexanol-
toluene, methylamine-n hexane, ethyl acetate-toluene-
isopropanol, hexane-toluene-paraffin mixtures, tetrahy-
drofuran-paraffin-cyclohexanol-water, tetrahydrofuran-
paraffin-isopropanol-cyclohexanol were investigated for 
the separation of artesunate and amodiaquine, 
respectively from excipients in their formulation. Paraffin-
n hexane   2:3 (v/v)  and ethyl  acetate–toluene   2.5:47.5  














0.05 12.8 0.0 0.0000 
0.10 12.8 0.1 0.0078 
0.125 12.8 0.1 0.0078 
0.25 12.8 0.2 0.0016 
0.50 12.8 0.3 0.0234 
1.0 12.8 0.3 0.0234 
2.0 12.8 0.4 0.0313 
3.0 12.8 0.4 0.0313 
4.0 12.8 0.4 0.0313 




Table 2b. Data for amodiaquine retention factor (Rf) values (Day 2). 
 
Concentration (µg/ml) Distance moved by mobile phase(solvent front Distance moved by sample Retention factor (Rf) 
0.05 12.5 0.0 0.000 
0.10  0.1 0.008 
0.125  0.1 0.008 
0.25  0.1 0.008 
0.50  0.2 0.016 
1.0  0.3 0.024 
2.0  0.3 0.024 
3.0  0.4 0.032 
4.0  0.4 0.032 








Distance moved by mobile 
phase(solvent front 




0.05 9.4 0.5 0.05 
0.10  0.7 0.07 
0.125  0.8 0.09 
0.25  1.5 0.16 
0.50  1.6 0.17 
1.0  1.6 0.17 
2.0  1.7 0.18 
3.0  1.8 0.19 
4.0  1.9 0.20 




(v/v) were found to result in best peak shapes for 
artesunate and amodiaquine, respectively. Artesunate 
and amodiaquine were satisfactorily resolved with 
retention factor (Rf) values ranging from 0.03-0.06 ± 
0.02-0.03 and 0.02-0.1 ± 0.01-0.07, respectively (Figures 
1 and 2). Pre-saturation of the TLC chamber and iodine 
chamber with mobile phase vapour and iodine vapour, 
respectively for 20 to 30 min ensured more reproducible 
migration of the drugs and better resolution. 
As recommended by International Conference on 
Harmonization (ICH, 1994), calibration plots were 
established for artesunate and amodiaquine standards 
using seventeen concentrations (0.001, 0.00125, 0.0025, 
0.005, 0.01, 0.0125, 0.025,  0.05,  0.1,  0.125,  0.25,  0.5,  




Table 3. Summary of the method validation data for artesunate and amodiaquine. 
 
Method characteristic   Artesunate  Amodiaquine 
Linear range (mg/ml)  
 
0.001 – 5.0  0.05 – 5.0 
   
Correlation coefficient (r) 
P = 0.01  
 0.873 – 0.895 0.859 – 0.945 
    
Repeatability of measurement of peak area  
(RSD, %, n = 3)  
 12.9  8.74 
   
Precision (RSD, %)    
Intraday (n = 6)  10.7 – 25.8  19.74 – 37.3 
Inter-day (n = 6) 10.68 – 20.2  19.74 – 8.2 
   
Specificity   Specific  Specific 














Figure 1. Plots of artesunate retention factor values against concentrations. 




Table 4a. Mean, standard deviations, number of samples and relative standard deviations (%RSD) of 
artesunate tablet. 
 
Variable  Mean Standard deviation N Relative standard deviation (%RSD) 
Rf1 0.032 0.022 17 68.8 
Rf2 0.063 0.029 17 46.5 




Table 4b. Mean, standard deviations, number of samples and relative standard deviations (%RSD) of amodiaquine 
tablet. 
 
Variable  Mean Standard deviation N Relative standard deviation (%RSD) 
Rf1 0.0197 0.0134 10 68.0 
Rf2 0.0200 0.0139 10 69.5 













Figure 2. Plots of amodiaquine retention factor values against its concentration. 




Table 5a. Correlation data for artesunate tablet. 
 
Parameter Concentration Rf1 Rf2 Rf3 
Concentration 
Pearson correlation 1 0.873** 0.895** 0.599* 
Sig. (2-tailed)  0.000 0.000 0.011 
N 17 17 17 17 
      
Rf1 
Pearson correlation 0.873** 1 0.975** 0.851** 
Sig. (2-tailed) 0.000  0.000 0.000 
N 17 17 17 17 
      
Rf2 
Pearson correlation 0.895** 0.975** 1 0.867** 
Sig. (2-tailed) 0.000 0.000  0.000 
N 17 17 17 17 
      
Rf3 
Pearson correlation 0.599* 0.851** 0.851** 1 
Sig. (2-tailed) 0.011 0.000 0.000  




Table 5b. Correlation data for amodiaquine. 
 
Parameter Concentration Rf1 Rf2 Rf3 
Concentration 
Pearson  correlation 1 0.858** 0.945** 0.770** 
Sig. (2-tailed)  0.001 00.000 00.009 
N 10 10 10 10 
      
Rf1 
Pearson correlation 0.859** 1 0.940** 0.938** 
Sig. (2-tailed) 0.001  0.000 0.000 
N 10 10 10 10 
      
Rf2 
Pearson correlation 0.945** 0.940** 1 0.894** 
Sig. (2-tailed) 0.009 0.000  0.000 
N  10 10 10 10 
      
Rf3 
Pearson correlation 0.770** 0.938** 0.894** 1 
Sig. (2-tailed) 0.009 0.000 0.000  




1.0, 2.0 3.0, 4.0 and 5.0 mg/ml) and ten concentrations 
(0.05, 0.1, 0.125, 0.25, 0.5, 1.0, 2.0 3.0, 4.0 and 5.0 
mg/ml) for artesunate and amodiaquine, respectively. 
The correlation coefficients for the plots range within 
0.873 and 0.895 for artesunate and 0.859 and 0.945 for 
amodiaquine (intra-day and inter-day correlation co-
efficients) as shown in Tables 5a and b. To test the 
specificity of the method, certain concentrations of 
artesunate and amodiaquine were spotted on the TLC 
plates and developed separately; this was repeated thrice 
for the same concentration. Excipients present in both 
formulations did not interfere with the peaks of artesunate 
and amodiaquine. When small changes were made to the 
method conditions, there were no marked changes in 
chromatographic behaviour, indicating that the method is 
robust. Correlations were fairly good. A relatively weak to 
fairly good linear association (R
2 
= 0.36 to 0.80) was 
observed between artesunate concentrations and their 
retention factors (Rf) and a fairly good linear association 
(R
2
 = 0.59 – 0.89) was observed for amodiaquine 
concentrations and their retention factors (Rf) values. The 
intraday and interday relative standard deviations (RSD) 
were in the ranges of 10.7 to 25.8% and 10.7 to 20.2% 
for artesunate and 8.2 to 19.74% and 8.2 to 37.3% for 
amodiaquine. RSD for measurement of peak area was 
12.9 and 8.74% for artesunate and amodiaquine, 
respectively. The detection limit was measured as the 
lowest concentration resulting to the lowest observable 
TLC peak height. According to this rule, artesunate and 
amodiaquine exhibited a detection limit of 0.001 and 0.05  




mg/ml, respectively. These results were reproducible and 





It is shown that our new TLC method achieved repro-
ducibility, repeatability, linearity and selectivity that 
compares favourably with those of GC, GC-MS, HPLC, 
HPTLC, spectrophotometry and other methods reported 
regularly in literatures. The results also meet ICH 
guidelines (ICH, Q2A and ICH, Q2B) for validation of 
pharmaceutical TLC methods. The proposed TLC 
method is simpler, less expensive, routine, more rapid, 
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